

**The YODA Project**  
**Research Proposal Due Diligence Assessment**

<b>Part 1: General Information</b>	
<b>YODA Project (Protocol) ID:</b>	2018-3126
<b>Date:</b>	3 May 2018
<b>Product Name:</b>	Infliximab/ Ustekinumab
<b>Therapeutic Area:</b>	Immunology
<b>Product Class:</b>	Antirheumatic Agents - Biologic Response Modifiers
<b>Condition(s) Studied:</b>	Crohn's Disease
<b>Protocol Number(s) and Title(s):</b>	<p><b>Infliximab:</b>  <b>NCT00207662</b> <b>C0168T21</b> ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF<math>\alpha</math> Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease  <b>NCT00207766</b> <b>C0168T26</b> ACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease  <b>NCT00094458</b> <b>C0168T67</b> Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE<sup>®</sup> (infliximab) and REMICADE plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn's Disease Naive to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease)</p> <p><b>Ustekinumab:</b>  <b>NCT00771667</b> <b>C0743T26</b> A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy  <b>NCT01369329</b> <b>CNT01275CRD3001</b> A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)  <b>NCT01369342</b> <b>CNT01275CRD3002</b> A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)  <b>NCT01369355</b> <b>CNT01275CRD3003</b> A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease</p>
<b>Part 2: Data Availability</b>	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
<b>Comments:</b>	

## The YODA Project Research Proposal Due Diligence Assessment

Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	
<b>Part 3: Data Availability Summary</b>	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes

<b>Part 4: Proposal Review</b>	
Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	